Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model.
Welters MJ, Filippov DV, van den Eeden SJ, Franken KL, Nouta J, Valentijn AR, van der Marel GA, Overkleeft HS, Lipford G, Offringa R, Melief CJ, van Boom JH, van der Burg SH, Drijfhout JW. Welters MJ, et al. Among authors: nouta j. Vaccine. 2004 Dec 2;23(3):305-11. doi: 10.1016/j.vaccine.2004.06.008. Vaccine. 2004. PMID: 15530672
Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers.
van Dissel JT, Arend SM, Prins C, Bang P, Tingskov PN, Lingnau K, Nouta J, Klein MR, Rosenkrands I, Ottenhoff TH, Kromann I, Doherty TM, Andersen P. van Dissel JT, et al. Among authors: nouta j. Vaccine. 2010 Apr 30;28(20):3571-81. doi: 10.1016/j.vaccine.2010.02.094. Epub 2010 Mar 11. Vaccine. 2010. PMID: 20226890 Clinical Trial.
Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection.
van Dissel JT, Soonawala D, Joosten SA, Prins C, Arend SM, Bang P, Tingskov PN, Lingnau K, Nouta J, Hoff ST, Rosenkrands I, Kromann I, Ottenhoff TH, Doherty TM, Andersen P. van Dissel JT, et al. Among authors: nouta j. Vaccine. 2011 Mar 3;29(11):2100-9. doi: 10.1016/j.vaccine.2010.12.135. Epub 2011 Jan 20. Vaccine. 2011. PMID: 21256189 Clinical Trial.
mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine.
Buhre JS, Pongracz T, Künsting I, Lixenfeld AS, Wang W, Nouta J, Lehrian S, Schmelter F, Lunding HB, Dühring L, Kern C, Petry J, Martin EL, Föh B, Steinhaus M, von Kopylow V, Sina C, Graf T, Rahmöller J, Wuhrer M, Ehlers M. Buhre JS, et al. Among authors: nouta j. Front Immunol. 2023 Jan 12;13:1020844. doi: 10.3389/fimmu.2022.1020844. eCollection 2022. Front Immunol. 2023. PMID: 36713457 Free PMC article.
Factors affecting IgG4-mediated complement activation.
Oskam N, Damelang T, Streutker M, Ooijevaar-de Heer P, Nouta J, Koeleman C, Van Coillie J, Wuhrer M, Vidarsson G, Rispens T. Oskam N, et al. Among authors: nouta j. Front Immunol. 2023 Jan 26;14:1087532. doi: 10.3389/fimmu.2023.1087532. eCollection 2023. Front Immunol. 2023. PMID: 36776883 Free PMC article.
37 results